StockData
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Fulgent Genetics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$20.10+0.29 (+1.46%)

Close on Oct 19, 2026

Market cap
$562.90M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 6, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 30, 2026During market hours$85.40M$-1.05$-0.58
Q1 FY2026
Ended Mar 31, 2026
May 1, 2026Before market open$71.10M$-0.80$-0.36
Q4 FY2025
Ended Dec 31, 2025
Feb 27, 2026Before market open$83.30M$-0.76$0.16
Q3 FY2025
Ended Sep 30, 2025
Nov 7, 2025Before market open$84.07M$-0.21$0.14
Q2 FY2025
Ended Jun 30, 2025
Aug 1, 2025Before market open$81.80M$-0.62$0.07
Q1 FY2025
Ended Mar 31, 2025
May 2, 2025Before market open$73.50M$-0.37$0.04
Q4 FY2024
Ended Dec 31, 2024
Feb 28, 2025Before market open$76.20M$-0.19$0.04
Q3 FY2024
Ended Sep 30, 2024
Nov 8, 2024Before market open$71.70M$-0.48$0.31
Q2 FY2024
Ended Jun 30, 2024
Aug 2, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 3, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 28, 2024Before market open–––

Company guidance

Outlook given with results on Jul 30, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Non-GAAP loss per sharenon-GAAPfull year 2026$-2.35 to $-2.22Lowered
Cash, cash equivalents, restricted cash, and investments in marketable securitiesfull year 2026$610.00MLowered
Non-GAAP lossnon-GAAPfull year 2026-$67.00M to -$63.00MLowered
Revenuefull year 2026$330.00M to $340.00MLowered

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Fulgent Genetics filed with the SEC